References
- Bellentani S, Scaglioni F, Marino M et al. Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 28(1), 155–161 (2010).
- Nascimbeni F, Pais R, Bellentani S et al. From nafld in clinical practice to answers from guidelines. J. Hepatol. 59(4), 859-871 (2013).
- Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 114(4), 842–845 (1998).
- Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig. Liver Dis. 41(9), 615–625 (2009).
- Abenavoli L, Milic N. Dietary intervention in non-alcoholic fatty liver disease. J. Acad. Nutr. Diet. 113(2), 211 (2013).
- Loria P, Adinolfi LE, Bellentani S et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian association for the study of the liver (AISF) expert committee. Dig. Liver Dis. 42(4), 272–282 (2010).
- Abenavoli L, Capasso R, Milic N et al. Milk thistle in liver diseases: past, present, future. Phytother. Res. 24(10), 1423–1432 (2010).
- Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 61(14), 2035–2063 (2001).
- Gazak R, Walterova D, Kren V. Silybin and silymarin–new and emerging applications in medicine. Curr. Med. Chem. 14(3), 315–338 (2007).
- Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst. Rev. 17(4), CD003620 (2007).
- Salamone F, Galvano F, Cappello F et al. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Transl. Res. 159(6), 477–486 (2012).
- Basiglio CL, Sánchez Pozzi EJ et al. Differential effects of silymarin and its active component silibinin on plasma membrane stability and hepatocellular lysis. Chem. Biol. Interact. 179(2–3), 297–303 (2009).
- Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J. Gastroenterol. 17(18), 2288–2301 (2011).
- Velussi M, Cernigoi AM, De Monte A et al. Long term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need, and malondialdehyde levels in cirrhotic diabetic patients. J. Hepatol. 26(4), 871–879 (1997).
- Hajaghamohammadi AA, Ziaee A, Raflei R. The efficacy of silymarin in decreasing transaminase activities in nonalcoholic fatty liver disease. A randomized controlled clinical trial. Hepat. Mon. 8, 191–195 (2008).
- Hasjiani E, Hasahemi SJ. Comparison of therapeutic effects of Silymarin and Vitamin E in nonalcoholic fatty liver disease: results of an open-label, prospective, randomized study. JJNPP 4, 8–14 (2009).
- Loguercio C, Federico A, Trappoliere M et al. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig. Dis. Sci. 52(9), 2387–2395 (2007).
- Loguercio C, Andreone P, Brisc C et al. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Radic. Biol. Med. 52(9), 1658–1665 (2012).
- Serviddio G, Bellanti F, Giudetti AM et al. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J. Pharmacol. Exp. Ther. 332(3), 922–932 (2010).
- Saller R, Brignoli R, Melzer J et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch. Komplementmed. 15(1), 9–20 (2008).